Description:

NANOPLATFORMS FOR DELIVERY OF INHIBITORS AND BIOLOGICS

INV-14023

INVENTORS:  Shifalika Tangutoori, Srinivas Sridhar

Description       

In prior art, many available drugs (such as PARP inhibitors) are difficult to deliver using existing platforms/delivery mechanisms.  Moreover, such drugs are available only in oral formulations that are associated with poor bioavailability.  Some of the other key limitations associated with existing formulations are insufficient accumulation at the target site as well as undesirable side effects.  This invention discloses a novel, nanoparticle based formulation for delivery of therapeutic agents and/or inhibitors that are otherwise difficult to deliver.

Value Proposition

The nanoparticle formulation:

•Involves use of biocompatible components

•Effectively minimizes toxicity of individual components

•Maximizes accumulation of therapeutic agents at the diseased site

•Is highly injectable as compared to existing formulations

•Is capable of being used as a mono-therapy or a dual drug delivery

•Is designed to target a tumor using passive or active methods

•Is further capable of being used in combination with chemo and radio therapies

•Has an increased bioavailability as compared to conventional platforms

•Would be commercially useful for treatment of various indications such as cancer, neurological disorders, traumatic brain injuries, CNS disorders, inflammation, urinary tract disorders, and respiratory system disorders

 

Intellectual Property status

Provisional Application 61/870,258

 

License status

Available for license

 

Patent Information:
For Information, Contact:
Mark Saulich
Associate Director of Commercialization
Northeastern University
m.saulich@northeastern.edu
Inventors:
Srinivas Sridhar
Tangutoori Shifalika
Keywords:
Drug Delivery
Nanomedicine